{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:30:18Z","timestamp":1778902218492,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved significantly recently; however, access to novel agents remains limited because of high costs. This study aimed to evaluate the systemic treatment patterns and survival outcomes for advanced HCC across different systemic treatment sequences under real-world resource constraints. Methods: This retrospective study was conducted at a tertiary center in Southern Thailand. The medical records of patients (n = 330) with advanced HCC treated with systemic therapy between 2010 and 2024 were reviewed. Outcomes included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Prognostic factors for OS were investigated. Results: First-line therapies included tyrosine kinase inhibitor (TKI; 69.7%), chemotherapy (23.3%), immunotherapy (IO)\/targeted therapy (3.6%), dual IO (1.8%), and IO monotherapy (1.5%). The median OS, PFS, and ORR for each cohort were 7.2, 5.2, 10.9, 8.5, and 8.6 months; 3.94, 3.22, 3.48, 6.19, and 2.69 months; and 9.6%, 10.4%, 16.7%, 0%, and 20.0%, respectively. OS improved with increasing lines of therapy (4.5, 12.2, 19.4, and 40.7 months for one to four lines, respectively). Portal vein tumor thrombus, ascites, elevated bilirubin level, high alpha-fetoprotein level, and poor Eastern Cooperative Oncology Group performance status were associated with poor prognosis; multiple treatment lines and overweight status were associated with improved OS. Conclusions: In this large real-world cohort, TKIs remained the mainstay effective treatment option because of limited access to IO-based regimens. Sequential systemic therapy significantly improved survival, emphasizing the importance of preserving treatment eligibility and multidisciplinary team involvement. Chemotherapy could be considered a viable option in resource-limited settings.<\/jats:p>","DOI":"10.3390\/cancers17172729","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:50:31Z","timestamp":1755863431000},"page":"2729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Systemic Treatment Patterns, Survival Outcomes, and Prognostic Factors in Advanced Hepatocellular Carcinoma: A 15-Year Experience from a Low-Resource Setting"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1265-7459","authenticated-orcid":false,"given":"Jirapat","family":"Wonglhow","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-3692","authenticated-orcid":false,"given":"Chirawadee","family":"Sathitruangsak","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-270X","authenticated-orcid":false,"given":"Patrapim","family":"Sunpaweravong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-4112","authenticated-orcid":false,"given":"Panu","family":"Wetwittayakhlang","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-4385","authenticated-orcid":false,"given":"Arunee","family":"Dechaphunkul","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/JHC.S270532","article-title":"A comparison of lenvatinib versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma: Selection criteria to guide physician\u2019s choice in a new therapeutic scenario","volume":"8","author":"Dipasquale","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s11864-023-01135-7","article-title":"Sequencing systemic therapy in hepatocellular carcinoma","volume":"24","author":"Ponvilawan","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial","volume":"41","author":"Qin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1634\/theoncologist.2014-0190","article-title":"Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: A subgroup analysis of the EACH study","volume":"19","author":"Qin","year":"2014","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wonglhow, J., Sunpaweravong, P., Sathitruangsak, C., and Dechaphunkul, A. (2024). LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: A single-center retrospective study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12040-z"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wonglhow, J., Sunpaweravong, P., Sathitruangsak, C., and Dechaphunkul, A. (2024). The performance of a survival nomogram and albumin-bilirubin grade as prognostic tools in advanced hepatocellular carcinoma treated with FOLFOX4. J. Pers. Med., 14.","DOI":"10.3390\/jpm14040403"},{"key":"ref_22","first-page":"294","article-title":"Epidemiology and treatment of hepatocellular carcinoma in Thailand","volume":"47","author":"Chonprasertsuk","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_23","first-page":"63","article-title":"Real-world use of immunotherapy for hepatocellular carcinoma","volume":"14","author":"Sara","year":"2023","journal-title":"Pragmat. Obs. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4103\/jcrt.jcrt_308_21","article-title":"Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study","volume":"19","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.4251\/wjgo.v15.i10.1796","article-title":"Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States","volume":"15","author":"Li","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11938-021-00346-x","article-title":"Recent progress in systemic therapy for hepatocellular cancer (HCC)","volume":"19","author":"Ghaziani","year":"2021","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40801-021-00286-z","article-title":"Real-world treatment patterns and health-resource utilization in patients with hepatocellular carcinoma (HCC) following failure of sorafenib: A retrospective chart review of 127 patients in South Korea","volume":"9","author":"Novick","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17588359231189425","DOI":"10.1177\/17588359231189425","article-title":"Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: Overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting","volume":"15","author":"Nault","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/1120009X.2024.2305066","article-title":"The prognostic factors in patients with advanced hepatocellular carcinoma: Impact of treatment sequencing","volume":"36","author":"Demirel","year":"2024","journal-title":"J. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Leyh, C., Ehmer, U., Roessler, D., Philipp, A.B., Reiter, F.P., Jeliazkova, P., Jochheim, L.S., Jeschke, M., Hammig, J., and Ludwig, J.M. (2022). Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: A real-world analysis. Cancers, 14.","DOI":"10.3390\/cancers14081975"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The obesity paradox in cancer: A review","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e213520","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of obesity with survival outcomes in patients with cancer: A systematic review and meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Himmelsbach, V., Pinter, M., Scheiner, B., Venerito, M., Sinner, F., Zimpel, C., Marquardt, J.U., Trojan, J., Waidmann, O., and Finkelmeier, F. (2022). Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers. Cancers, 14.","DOI":"10.3390\/cancers14071722"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.12688\/f1000research.145493.2","article-title":"Hepatocellular carcinoma: Advances in systemic therapies","volume":"13","author":"Wu","year":"2024","journal-title":"F1000Research"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:45Z","timestamp":1760034825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":34,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172729"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172729","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}